GlassScriptPhysician profile
Maurine E Horowitz
NPI 1215093570
$8,873.97
in general payments reported to CMS, 2019-2025
35 companies · $606 in 2025
The $606 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,487 · 2020: $159 · 2021: $544 · 2022: $689 · 2023: $563 · 2024: $827 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.42 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $4,930.25 | 2019 | |
| Abbvie INC. | $631.69 | 2019-2024 | |
| Astellas Pharma US INC | $503.17 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $354.52 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $220.52 | 2023-2025 | Myfembree, Gemtesa |
| Aspira Women'S Health INC | $212.36 | 2022-2025 | Ova1 |
| Hologic Sales and Service, LLC | $202.09 | 2019-2024 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Daiichi Sankyo INC. | $199.45 | 2019-2025 | Injectafer |
| Pfizer INC. | $176.29 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $163.16 | 2019-2020 | |
| Amgen INC. | $158.77 | 2019-2024 | Evenity, Prolia |
| Myovant Sciences INC. | $129.26 | 2021-2022 | |
| Organon LLC | $116.03 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $112.66 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $108.88 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $100.36 | 2023-2025 | Accrufer |
| Evofem Biosciences, INC. | $60.74 | 2021-2022 | |
| Sage Therapeutics, LLC | $55.04 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $53.41 | 2019-2023 | Balcoltra |
| Agile Therapeutics, INC. | $47.56 | 2021-2022 | |
| Exact Sciences Corporation | $43.48 | 2024 | Cologuard Collection Kit |
| Ascend Therapeutics US, LLC | $41.33 | 2021-2022 | |
| Coopersurgical, INC. | $40.80 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $38.37 | 2024-2025 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $33.60 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $28.09 | 2020-2021 | |
| Allergan, INC. | $24.04 | 2019 | |
| Minerva Surgical, INC | $14.67 | 2023 | |
| Seqirus USA INC | $13.97 | 2022 | |
| Scynexis, INC. | $13.08 | 2022 | |
| Merck Sharp & Dohme LLC | $12.58 | 2020 | |
| Becton, Dickinson and Company | $12.37 | 2021 | |
| Lupin INC. | $10.93 | 2019 | |
| Meditrina | $10.45 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurine Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.